BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12778012)

  • 1. Immunotherapy and biological modifiers for the treatment of malignant brain tumors.
    Marras C; Mendola C; Legnani FG; DiMeco F
    Curr Opin Oncol; 2003 May; 15(3):204-8. PubMed ID: 12778012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma.
    Sonabend AM; Dana K; Lesniak MS
    Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy approaches for malignant glioma from 2007 to 2009.
    Johnson LA; Sampson JH
    Curr Neurol Neurosci Rep; 2010 Jul; 10(4):259-66. PubMed ID: 20424975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
    Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
    Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment modalities for malignant gliomas with reference to their pathophysiology].
    Kobayashi S; Takakura K
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):11-7. PubMed ID: 3942392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for glioma: Current management and future application.
    Xu S; Tang L; Li X; Fan F; Liu Z
    Cancer Lett; 2020 Apr; 476():1-12. PubMed ID: 32044356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapies for malignant glioma.
    Lukas RV; Boire A; Nicholas MK
    Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S29-36. PubMed ID: 18076315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
    Pollack IF; Okada H; Chambers WH
    Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of pediatric gliomas: implications for the development of future therapies.
    Pytel P
    Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S51-60. PubMed ID: 18076319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
    Lee Y; Bigner DD
    Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy and Response Assessment in Malignant Glioma: Neuro-oncology Perspective.
    Bagley SJ; Desai AS; Nasrallah MP; O'Rourke DM
    Top Magn Reson Imaging; 2020 Apr; 29(2):95-102. PubMed ID: 32271286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunobiology and immunotherapeutic targeting of glioma stem cells.
    Madany M; Thomas TM; Edwards L; Yu JS
    Adv Exp Med Biol; 2015; 853():139-66. PubMed ID: 25895711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell- and peptide-based immunotherapeutic approaches for glioma.
    Yamanaka R
    Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.
    Wang X; Zhao HY; Zhang FC; Sun Y; Xiong ZY; Jiang XB
    Cancer Invest; 2014 Nov; 32(9):451-7. PubMed ID: 25259676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of skull base tumors.
    Prabhu SS; Demonte F
    Curr Opin Oncol; 2003 May; 15(3):209-12. PubMed ID: 12778013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapies for malignant gliomas.
    Cavaliere R; Wen PY; Schiff D
    Neurol Clin; 2007 Nov; 25(4):1141-71, x. PubMed ID: 17964029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy approaches in the treatment of malignant brain tumors.
    Dunn-Pirio AM; Vlahovic G
    Cancer; 2017 Mar; 123(5):734-750. PubMed ID: 27875627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials in cellular immunotherapy for brain/CNS tumors.
    Badhiwala J; Decker WK; Berens ME; Bhardwaj RD
    Expert Rev Neurother; 2013 Apr; 13(4):405-24. PubMed ID: 23545055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular immunity and immunotherapy of brain tumors.
    Prins RM; Liau LM
    Front Biosci; 2004 Sep; 9():3124-36. PubMed ID: 15353342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of interferon-alpha-induced dendritic cells in the therapy of patients with malignant brain gliomas.
    Leplina OY; Stupak VV; Kozlov YP; Pendyurin IV; Nikonov SD; Tikhonova MA; Sycheva NV; Ostanin AA; Chernykh ER
    Bull Exp Biol Med; 2007 Apr; 143(4):528-34. PubMed ID: 18214316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.